Expanding Roles for GLP-1 Receptor Agonists: Are You Up to Date?

During the 2025 American Association of Clinical Endocrinology (AACE) Annual Meeting, Daniel Drucker, OC, MD, FRCPC, FRSC, FRS, presented a forward-looking perspective on the rapidly expanding applications of GLP-1 receptor agonists. While traditionally used to manage type 2 diabetes and obesity, these medications are now being studied for their effects in conditions such as heart failure, chronic kidney disease, and even Alzheimer disease. As the therapeutic horizon broadens, clinicians must weigh efficacy, safety, and cost-effectiveness across diverse patient populations. This quiz challenges your understanding of GLP-1 therapy’s emerging roles and clinical implications.

©2025 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Consultant360 or HMP Global, their employees, and affiliates.